Kirsten Minden

Outcomes in JIA have greatly improved, but we can still do better

Abstract Outcomes for children and adolescents with juvenile idiopathic arthritis (JIA) have improved substantially over the past two decades, driven by biologic and targeted synthetic DMARDs, treat-to-target strategies with regular standardized assessments, and multidisciplinary...